Smith & Nephew Trims Revenue View but Holds Profit Guide on Cost Cuts and Tariff Refunds

Q2 miss in U.S. Orthopaedics and Bioactives forces lower growth guidance, yet efficiency savings, tariff offsets, and new products keep profit trajectory intact.

SNN · Earnings Call · 2026-08-04

A Lower Revenue Outlook, But Profit Is Defended

When Smith & Nephew reported Q2 2026 results on August 4, the company delivered a clear but nuanced message: growth has slowed, but discipline has improved. Underlying revenue growth of just 1.6% fell short of expectations, prompting a cut to full-year guidance from ~6% to ~4%. Yet the company held its trading profit guidance, free cash flow outlook, and ROIC target intact, thanks to a sharp step-up in efficiency savings and a favorable net tariff position. “we now expect underlying revenue growth of around 4% for 2026” — Deepak Nath, Chief Executive Officer · 2026-08-04 said CEO Deepak Nath. He quickly added that “trading profit was strong at $566 million” — Deepak Nath, Chief Executive Officer · 2026-08-04 for the quarter, underscoring the resilience of the model. The revised outlook is anchored on a second-half recovery expected to deliver 5%–5.5% growth, with drivers across all three business units. The weakness was concentrated in U.S. Orthopaedics and Advanced Wound Bioactives. In Orthopaedics, knees remained weak due to a deliberate portfolio gap and a slower-than-expected build of LEGION MS. Hips were temporarily impacted by a delay in set deployment for CATALYSTEM against a tough comparator. In Wound, Skin Subs continued to face reimbursement headwinds, and SANTYL was hit by prior authorization friction and distributor ordering dynamics. However, Sports Medicine & ENT grew 8.6% with double-digit growth in joint repair and key platforms like REGENETEN.

Efficiency Savings and Tariff Refunds Rescue the P&L

The profit story is the real headline. Despite the revenue miss, trading profit ex-M&A grew 9% year-on-year, supported by efficiency savings that far exceeded expectations. CFO John Rogers noted, “We have now achieved $330 million of cumulative savings since launching these programs… reaching the lower end of the $325 million to $375 million target… more than a year ahead of schedule.” — John Rogers, Chief Financial Officer · 2026-08-04 The company increased its 2026 savings target from $150 million to $200 million, with most incremental savings coming from manufacturing and procurement. Tariffs also turned out to be broadly neutral, as refunds offset the forecast headwind. This cost discipline is not at the expense of growth. Management emphasized that investments in R&D and commercial expansion have been ring-fenced, with headcount added in Sports and Wound. The bridge showed $33 million invested in growth initiatives, while $128 million of efficiency savings flowed through. The result was a 60 bps improvement in gross margin and an 18.3% trading margin, in line with the original profit guide.

Innovation Pipeline and a Confident Second Half

Looking ahead, management positioned the second half as a step-up driven by a cluster of new product launches. The LANDMARK launch in knees—first cementless, then cemented—is expected to fill the portfolio gap that has held back U.S. Orthopaedics. FDA approval of TESSA, the spatial surgery platform, and the early momentum of CARTIHEAL AGILI-C add to the innovation story. In Wound, ALLEVYN COMPLETE CARE and LEAF 3.0 are slated to contribute, while PICO is being expanded geographically. Deepak Nath pushed back on concerns about the midterm outlook, reaffirming the company's structural growth potential:

we are fundamentally a 6% to 7% growth company
Deepak Nath, Chief Executive Officer · 2026-08-04

He cited a pipeline of new products across all three business units, including HIP execution on CORI and a broader robotic ecosystem. This quarter's message is that Smith & Nephew is navigating a challenging top-line environment with improved operational control. The guidance cut is real, but the maintenance of profit, cash flow, and ROIC targets suggests the business is becoming more resilient—a key theme for investors. As John Rogers reminded, one extra trading day in Q4 and lapping of skin substitute headwinds should give additional support to the back-half acceleration. Whether the company can deliver on that promise will be the key question for the remainder of 2026.